Last reviewed · How we verify
Triple therapy with ritonavir
Ritonavir is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins and maturation of infectious HIV particles.
Ritonavir is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins and maturation of infectious HIV particles. Used for HIV-1 infection (as part of antiretroviral combination therapy), Pharmacokinetic booster for other protease inhibitors in combination antiretroviral regimens.
At a glance
| Generic name | Triple therapy with ritonavir |
|---|---|
| Sponsor | Sociedad Andaluza de Enfermedades Infecciosas |
| Drug class | HIV protease inhibitor |
| Target | HIV-1 protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Ritonavir inhibits the HIV-1 protease enzyme, which is essential for processing viral precursor proteins into functional structural and enzymatic proteins. By blocking this protease activity, ritonavir prevents the formation of mature, infectious viral particles. In triple therapy regimens, ritonavir is often used as a pharmacokinetic booster at sub-therapeutic doses to inhibit cytochrome P450 metabolism and increase plasma concentrations of other protease inhibitors.
Approved indications
- HIV-1 infection (as part of antiretroviral combination therapy)
- Pharmacokinetic booster for other protease inhibitors in combination antiretroviral regimens
Common side effects
- Gastrointestinal disturbances (nausea, diarrhea, abdominal pain)
- Taste perversion
- Hepatotoxicity
- Lipid abnormalities (elevated triglycerides and cholesterol)
- Hyperglycemia
- Lipodystrophy
Key clinical trials
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses (PHASE2)
- Efficacy of Atazanavir/Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression (PHASE3)
- ANRS 12372 MODERATO Study (PHASE3)
- Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People (NA)
- A Study to Assess Effectiveness and Safety of Fixed Dose Combination of Lopinavir/Ritonavir (LPV/r) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Patients After Switching From Kaletra in the Routine Clinical Settings of Russian Federation
- Strategy for Maintenance of HIV Suppression With Once Daily Integrate Inhibitor+Darunavir/Ritonavir in Children (PHASE2, PHASE3)
- Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: